Product Information
DOFETILIDE 125 MCG CAPSULE is a generic product labeled by Sigmapharm Laboratories LLC, priced at $0.2026 per EA under NDC 42794004410. Its NADAC has been published 421 times since Sep 12, 2018.
FDA first approved this application on Mar 26, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
125 ug/1
Manufacturer
Sigmapharm Laboratories LLCNDC
42794004410
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DOFETILIDEApproval Type
Generic (ANDA)
FDA Application
ANDA207746FDA Approved
3/26/2018
TE Code
AB
On Market Since
6/11/2018
Pharmacological Classes
Price Statistics
The NADAC for DOFETILIDE 125 MCG CAPSULE has been published 421 times since Sep 12, 2018, and over the history we have for it it has declined 95.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2026 per EA |
|---|---|
| All-time high | $4.6718 (Sep 12, 2018) |
| All-time low | $0.1776 (May 22, 2024) |
| 52-week high | $0.2198 |
| 52-week low | $0.1925 |
| Median price | $0.6483 |
| Average price | $1.1626 |
| Largest weekly change | +110.6% (Jan 18, 2023) |
| Weeks tracked | 421 |
| Tracking since | Sep 12, 2018 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Dofetilide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sigmapharm Laboratories LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Dofetilide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antiarrhythmic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DOFETILIDE 125 MCG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for DOFETILIDE 125 MCG CAPSULE, manufactured by Sigmapharm Laboratories LLC, is $0.2026 per EA (NDC 42794004410), effective Sep 30, 2026.
How has the price of DOFETILIDE 125 MCG CAPSULE changed over time?
Over the history we have for it, the NADAC for DOFETILIDE 125 MCG CAPSULE has declined 95.7%. It has been tracked across 421 weekly CMS publications since Sep 12, 2018.
What are the highest and lowest recorded NADAC prices for DOFETILIDE 125 MCG CAPSULE?
Since Sep 12, 2018, the NADAC for DOFETILIDE 125 MCG CAPSULE has ranged from a low of $0.1776 (May 22, 2024) to a high of $4.6718 (Sep 12, 2018), with a median of $0.6483 per EA.
Are there cheaper alternatives to DOFETILIDE 125 MCG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of DOFETILIDE 125 MCG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DOFETILIDE 125 MCG CAPSULE?
DOFETILIDE 125 MCG CAPSULE (NDC 42794004410) is labeled by Sigmapharm Laboratories LLC, and CMS classifies it as a generic product.